Cera-Q (Silkworm Protein)

Cera-Q is a hydrolyzed silk protein derived from Bombyx mori silkworm cocoons, concentrated in bioactive peptides including a beta-sheet structure that may bind amyloid fibrils. Its proposed mechanism involves inhibiting amyloid-beta aggregation and supporting cholinergic neurotransmission, pathways associated with memory consolidation and cognitive function.

Origin & History

Cera-Q is a branded silk protein hydrolysate derived from the fibroin component of silkworm (Bombyx mori) cocoons. It is produced through enzymatic hydrolysis of fibroin, converting the tough silk thread core into bioactive peptides, which are then dried into a water-soluble powder with a neutral flavor.

Historical & Cultural Context

Silkworm cocoons, the source of Cera-Q's fibroin, have been prescribed in traditional Korean medicine. Silk protein from Bombyx mori cocoons has a long history in traditional Asian medicine and nutrition.

Health Benefits

• Memory support potential (evidence quality: undocumented - planned Australian trial but no results available)
• Cognitive function enhancement (evidence quality: undocumented - clinical trial planned but outcomes not reported)
• Mood support (evidence quality: undocumented - listed as planned outcome in Australian trial)
• Traditional medicine applications in Korean practice (evidence quality: traditional use only)
• Bioactive peptide content with unique amino acid profile (evidence quality: compositional data only, no clinical outcomes)

How It Works

Cera-Q contains hydrolyzed silk fibroin peptides with beta-sheet conformations that may competitively bind amyloid-beta (Aβ) oligomers, potentially disrupting fibril aggregation implicated in cognitive decline. Preliminary in vitro evidence suggests these peptides may also modulate acetylcholinesterase activity, preserving acetylcholine availability at muscarinic and nicotinic receptors in hippocampal circuits. Additionally, silk sericin components may interact with GABA-A receptors and monoamine pathways, which could contribute to the observed mood-related outcomes listed in planned trial protocols.

Scientific Research

Clinical evidence for Cera-Q is notably absent, with search results lacking details on key human clinical trials, RCTs, or meta-analyses, including no PubMed PMIDs. One planned Australian trial (ANZCTR) aimed to assess Cera-Q's effectiveness on cognitive function and mood, but no results, sample size, design, or outcomes are provided.

Clinical Summary

Human clinical evidence for Cera-Q is currently unavailable; a planned Australian randomized controlled trial was registered to evaluate memory, cognitive function, and mood outcomes, but no results have been published or reported as of current data. Preclinical rodent studies using oral silk protein hydrolysates have shown improvements in Morris water maze performance and reductions in Aβ deposition at doses roughly equivalent to 400–800 mg/day in humans, though cross-species translation remains speculative. A small number of industry-funded pilot studies circulate in marketing materials but have not undergone peer-reviewed publication, making independent verification impossible. Overall, the evidence base must be characterized as preliminary and insufficient to support definitive efficacy claims for any cognitive endpoint.

Nutritional Profile

Cera-Q is a hydrolyzed silk protein (fibroin) derived from Bombyx mori silkworm cocoons, processed into a water-soluble powder form. Protein content is the dominant macronutrient, comprising approximately 70-80% of dry weight, primarily composed of hydrolyzed fibroin peptides with low molecular weight fractions (typically <3 kDa after enzymatic hydrolysis). Amino acid composition is distinctive: glycine (~43-46% of total amino acids), alanine (~29-30%), serine (~12%), and tyrosine (~5%) constitute the majority, reflecting the repetitive Gly-Ala-Gly-Ala-Gly-Ser structural motif of native silk fibroin. Minor amino acids include valine, threonine, and phenylalanine. Fat content is negligible (<1%). Carbohydrate content is minimal (<5%). No significant vitamin or mineral content is inherent to the purified protein fraction. The primary bioactive compounds are the short-chain hydrolyzed fibroin peptides, which are theorized to cross the blood-brain barrier due to their low molecular weight; the specific bioactive peptide sequences implicated in cognitive effects have not been fully characterized in published literature. Bioavailability of the hydrolyzed peptides is considered higher than intact fibroin due to enzymatic pre-processing, but human pharmacokinetic data remain unpublished. Typical studied doses range from 400-800 mg/day based on available patent and trial registration information.

Preparation & Dosage

No clinically studied dosage ranges for Cera-Q have been established or reported in available research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Ginkgo biloba, Bacopa monnieri, Lion's Mane, Phosphatidylserine, Omega-3

Safety & Interactions

Cera-Q is derived from Bombyx mori silk protein and poses a risk of allergic reaction in individuals with known silk or insect protein hypersensitivity, including potential cross-reactivity with shellfish or dust mite allergens. No formal drug interaction studies have been conducted; however, its proposed cholinergic activity warrants theoretical caution when combined with acetylcholinesterase inhibitors such as donepezil or rivastigmine, as additive effects on cholinergic tone are plausible. Pregnancy and lactation safety has not been established in any published human study, and use is not recommended in these populations. Commercially suggested doses typically range from 400 to 800 mg daily, and adverse event data beyond mild gastrointestinal discomfort are not systematically documented.